Charlene Porter

Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer

Charlene Porter, Sylvia Armstrong‐Fisher, Tim Kopotsha et al. · Journal of Reproductive Immunology · 2016 · 114 citations · Full text

Medicine, Immunology, Pharmacology +17

Evaluation of the E test by using selected gram-positive bacteria

J H Ngui-Yen, Elizabeth Bryce, Charlene Porter et al. · Journal of Clinical Microbiology · 1992 · 35 citations · Full text

Life Sciences, Microbiology, Antimicrobial Pharmacotherapy +12

Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport

Nigel M. Stapleton, Sylvia Armstrong‐Fisher, Jan Terje Andersen et al. · Molecular Immunology · 2018 · 19 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

W1208 No Significant Transfer of Certolizumab Pegol Compared With IgG in the Perfused Human Placenta In Vitro

Charlene Porter, Tim Kopotsha, Bryan John Smith et al. · Gastroenterology · 2010 · 14 citations · Full text

Life Sciences, Obstetrics, Pharmacokinetics +14

Approach to Assessment of New Swabs and Viral Transport Media for SARS-CoV-2 Testing

Kerstin Locher, Billie Velapatiño, Mélissa Caza et al. · Journal of Clinical Microbiology · 2020 · 12 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +15